Alvogen terminates NRX-101 pact; NRx eyes accelerated FDA filing

NRX Pharmaceuticals, Inc.

Alvogen terminated exclusive development and license agreement for NRX-101 effective June 21, 2024.
Alvogen claims $4,502,705 in advanced amounts; parties to negotiate royalty within 30 days.
NRx plans Accelerated Approval filing this year for suicidal bipolar depression, citing trial data.
Company continues NDA submission for intravenous ketamine (NRX-100) in 2024.
NRx estimates $3.7B addressable market for NRX-101 in high-risk patients without viable alternatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.